Skip to main content

Table 1 Losartan does not interfere with the metabolism and uptake of MPTP.

From: Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra

(a) MPP+ levels in the striatum and substantia nigra of C57BL/6 mice
Treated Groups Striatum Substantia nigra
MPTP 0.27 ± 0.03 μg MPP+/g tissue 0.28 ± 0.12 μg MPP+/g tissue
MPTP+ Losartan 0.26+0.04 μg MPP+/g tissue 0.22 ± 0.05 μg MPP+/g tissue
(b) Dopamine uptake in ventral mesencephalic cultures
Control 68.1 ± 11.2 fmol/sec  
Losartan (1 μM) 72.7 ± 7.9 fmol/sec  
Losartan (10 μM) 76.2 ± 14.5 fmol/sec  
  1. (a) MPP+ levels in the striatum and substantia nigra of C57BL/6 mice were measured by HPLC analysis 60 min after MPTP injection regimen and were compared to MPTP injected mice pretreated with the AT1 receptor antagonist losartan (n = 3). (b) Dopamine uptake levels in VM cultures treated with media control, 1 and 10 μM losartan (n = 3).